Drug-maker QLT Inc. says sales of its prostate cancer drug Eligard will grow faster than originally expected this year and already helped boost revenues and profit in the second quarter. The higher sales may also increase the company's chance of selling Eligard, which QLT put on the block many months agoGlobal sales of Eligard rose 12 per cent to $67.6-million (U.S.) in the April-June period compared to last year. QLT-T (TSX) rose 17 cents to $3.57.
Sunday, Aug. 30, 2015 10:25AM EDT
Friday, Aug. 28, 2015 5:25PM EDT
Sunday, Aug. 30, 2015 12:00PM EDT